Multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms

Nicolas Alcala1, Catherine Voegele1, Lise Mangiante1,2

  • 1Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon 69008, France.

Gigascience
|March 7, 2024
PubMed
Abstract

Insights

Researchers created the first multi-omic dataset for patient-derived tumor organoids (PDTOs) from rare neuroendocrine tumors. This comprehensive dataset, including genomic and histopathological data, will advance precision medicine and cancer research for these understudied diseases.

Area of Science:

  • Oncology
  • Genomics
  • Biotechnology

Background:

  • Organoids are 3D models mimicking organ structure and function.
  • Patient-derived tumor organoids (PDTOs) show promise for precision medicine.
  • PDTOs are currently limited to a few cancer types.

Purpose of the Study:

  • To generate the first multi-omic dataset of PDTOs from rare pulmonary neuroendocrine tumors.
  • To provide comprehensive genomic and histopathological data for understudied neuroendocrine neoplasms.
  • To facilitate future research in drug screening and carcinogenesis mechanisms.

Main Methods:

  • Whole-genome sequencing (WGS) and RNA-sequencing (RNA-seq) of PDTOs and matched parental tumors.
  • Generation of a multi-omic dataset including 47 RNA-seq and 33 WGS samples.
  • Development of a random forest classifier to detect variants in tumor-only RNA-seq using WGS data.
  • Inclusion of histopathological images (H&E, brightfield, IHC) for diagnosis.

Main Results:

  • Generated a novel multi-omic dataset for PDTOs from pulmonary neuroendocrine tumors (n=12), ileal neuroendocrine tumors (n=6), and large-cell neuroendocrine carcinoma (n=5).
  • Provided raw and processed data, quality control metrics, and analysis scripts for data reuse.
  • Reported gene expression data, somatic small variant calls, and histopathological images.

Conclusions:

  • The generated dataset is crucial for future studies utilizing this PDTO biobank.
  • Enables drug screening for novel therapies in rare neuroendocrine tumors.
  • Supports investigations into the mechanisms of carcinogenesis in understudied diseases.

Related Concept Videos